Drug Profile
PK 048
Alternative Names: PK-048Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator PharmaKure
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in United Kingdom
- 27 Sep 2016 PK 048 is available for licensing as of 27 Sep 2016. http://www.pharmakure.com/drug.html
- 27 Sep 2016 Preclinical trials in Alzheimer's disease in United Kingdom (unspecified route)